Ho Yin Lo

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. ncbi 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket
    Ho Yin Lo
    Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, P O Box 368, Ridgefield, CT 06877, USA
    Bioorg Med Chem Lett 18:6218-21. 2008
  2. ncbi Itk inhibitors: a patent review
    Ho Yin Lo
    Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT 06877, USA
    Expert Opin Ther Pat 20:459-69. 2010
  3. ncbi Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain
    Ho Yin Lo
    Boehringer Ingelheim Pharmaceuticals Inc, Biomolecular Screening, 900 Ridgebury Rd, PO Box 368, Ridgefield, CT 06877, USA
    Bioorg Med Chem Lett 20:6379-83. 2010
  4. ncbi Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) region
    Ho Yin Lo
    Boehringer Ingelheim Pharmaceuticals Inc, Medicinal Chemistry, Ridgefield, CT 06877, USA
    Bioorg Med Chem Lett 21:4533-9. 2011

Detail Information

Publications4

  1. ncbi 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket
    Ho Yin Lo
    Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, P O Box 368, Ridgefield, CT 06877, USA
    Bioorg Med Chem Lett 18:6218-21. 2008
    ..Significant improvement on binding affinity and cellular activity were obtained through the trans-stilbene-like antagonists. Several compounds showed inhibitory activity in an IL-2 functional assay...
  2. ncbi Itk inhibitors: a patent review
    Ho Yin Lo
    Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT 06877, USA
    Expert Opin Ther Pat 20:459-69. 2010
    ..The prospects for Itk inhibitors will rely on the quality of the compound and the validity of the target in patients within the selected therapeutic area...
  3. ncbi Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain
    Ho Yin Lo
    Boehringer Ingelheim Pharmaceuticals Inc, Biomolecular Screening, 900 Ridgebury Rd, PO Box 368, Ridgefield, CT 06877, USA
    Bioorg Med Chem Lett 20:6379-83. 2010
    ..Lead optimization efforts to replace the aniline core are also described. In particular, 2-pyridine, 3-pyridine and pyridazine analogs are potent sEH inhibitors with favorable CYP3A4 inhibitory and microsomal stability profiles...
  4. ncbi Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) region
    Ho Yin Lo
    Boehringer Ingelheim Pharmaceuticals Inc, Medicinal Chemistry, Ridgefield, CT 06877, USA
    Bioorg Med Chem Lett 21:4533-9. 2011
    ..Among the P(1) replacements, benzoisothiazole prevents the formation of GSH conjugate and an in silico analysis of oxidative potentials agreed with the experimental outcome...